The content on this page is designed for Australia. Check courses designed for Canada (EN)
This course has expired. View available courses.
Oncology
Optimising outcomes with sunitinib for metastatic renal cell carcinoma (mRCC): focus on anticipating and managing adverse effects – Certificate of Completion
DURATION
PROFESSION
Specialist
# OF CREDITS
2
ACCREDITATION
Certificate of Completion
EXPIRY DATE
2018-09-12
Learning objectives
On completion of this program, participants will be better able to:
- Describe current metastatic renal cell carcinoma (mRCC) treatment options and sunitinib management practices
- Manage toxicities of sunitinib treatment and interpret their possible prognostic value
- Recognise the benefits of a multi-disciplinary team approach when treating a patient with RCC
- Recall second-line treatment options and the current data supporting these options
Cost of course:
Free